Cytokine News and Research

RSS

Effects of chronic stress associated with increased inflammatory signaling within brain circuits

Anxiety and depression are significantly heightened during times of great stress such as the COVID-19 pandemic.

4 Jun 2020

COVID-19 pandemic may cause long-term effects and increase healthcare costs, says GlobalData

As many COVID-19 patients may experience long-term complications from the illness such as intensive care unit delirium, post-traumatic stress disorder, lung damage, heart damage and possible neurological issues, GlobalData expects the market for these treatments to increase due to the COVID-19 pandemic as recovered patients may need long-term care for these issues after being released from the intensive care unit and the hospital.

4 Jun 2020

Study says vitamin-magnesium combo may reduce severity of COVID-19 in seniors

The COVID-19 pandemic that began in late December 2019 has spread to over 188 countries and territories, causing over 6.5 million cases and 385,000 deaths. With no effective therapeutic COVID-19 drug or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in sight, researchers are exploring different strategies to limit its spread and mortality.

4 Jun 2020

Hesperos’ immune system-on-a-chip emulates immune reactions for tissue damage and acute inflammation

Hesperos Inc., pioneers of the Human-on-a-Chip in vitro system, today announced the publication of a new peer-reviewed publication that describes how the company’s technology can be used to investigate immune responses following treatment with biological therapeutics for multi-organ systemic diseases, including cancer, infectious diseases and inflammatory disorders.

4 Jun 2020

Genetic variations linked to COVID-19 severity

A new report by researchers from Thailand's Mahidol University and published on the preprint server medRxiv in May 2020 reports that the clinical severity of COVID-19 may be linked to the genetic makeup of the patient in addition to external factors.

3 Jun 2020

Octapharma extends support for COVID-19 study following promising preliminary data

Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.

3 Jun 2020

Silent hypoxia and its role in COVID-19 detection

News-Medical speaks to Dr. Albert Rizzo about silent hypoxia and how it is occurring in individuals that are suffering from COVID-19.

3 Jun 2020

Does smoking increase COVID-19 risk?

The COVID-19 pandemic continues to smolder and smoke in many parts of the world, with over 100,000 cases, and more than 3,000 deaths reported every day. Many factors are responsible for the higher risk of infection in certain specific population subgroups are known.

2 Jun 2020

A cytokine pattern that predicts adverse outcomes in COVID-19

A new study published on the preprint server medRxiv in May 2020 reports the discovery of a predictive pattern of cytokines in COVID-19 infection that could guide clinical management if validated.

2 Jun 2020

Specific immune suppression leads to severe COVID-19 disease

A new study published online on the preprint server medRxiv in May 2020 reports that specific changes in the way the human immune system responds to COVID-19 determine whether the individual develops moderate or severe illness.

2 Jun 2020

Study highlights potential benefits of new drug for inflammatory diseases

New research conducted by the University of Liverpool and AKL Research and Development Ltd, published in Inflammopharmacology, highlights the potential benefits of a new drug treatment on the human body's immune response in inflammation.

1 Jun 2020

How COVID-19 affects the nervous system

A new paper published in the journal JAMA Neurology in May 2020 discusses the presentation and complications of COVID-19 with respect to the nervous system.

31 May 2020

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.

31 May 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Researchers review all clinical and research findings related to COVID-19

Due to the devastating worldwide impact of COVID-19, the illness caused by the SARS-CoV-2 virus, there has been unprecedented efforts by clinicians and researchers from around the world to quickly develop safe and effective treatments and vaccines.

29 May 2020

Rare deadly disease linked to coronavirus infection seen in children

Now, new evidence has shown that children with coronavirus disease (COVID-19) experience a Kawasaki-like illness, called multisystem inflammatory syndrome in children (MIS-C). The complication is akin to toxic shock syndrome, a condition that occurs due to sepsis. Though rare, the condition is life-threatening.

29 May 2020

Transgenic mouse model of HLH may play key role in saving lives during COVID-19

A transgenic mouse developed at Cincinnati Children's to model the deadly childhood immune disease HLH (hemophagocytic lymphohistiocytosis) may play a key role in saving lives during the COVID-19 virus pandemic.

28 May 2020

Researchers are taking inventory of drugs used to treat COVID-19

With doctors and researchers around the world searching for effective treatments for COVID-19, many drugs approved to treat other diseases are being used in hopes that they'll be effective against the virus, a use that's known as "off-label."

27 May 2020

What affects the case fatality rate of COVID-19? Analysis of top 50 affected countries

Ever since the beginning of the international spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease, researchers have been trying to identify the risk factors that increase the chances of infection. Now, a new study published on the preprint server medRxiv in May 2020 discusses various potential factors and reports the observed associations.

27 May 2020

Montefiore and Einstein evaluate a new drug combination to fight COVID-19

Montefiore Health System Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection.

26 May 2020